Injections work, but plenty of people do not want them. This is what we know about orforglipron, the oral GLP-1 pill that everyone assumed was coming and that took longer than expected. For years the GLP-1 conversation offered exactly one delivery route. The pill has arrived. The question now is what it changes for a real patient sitting with real options in 2026.
Orforglipron is a daily oral tablet, a small-molecule GLP-1 that does not require fasting, water restrictions or injection and in trials it produced average weight loss of roughly 11 percent of body weight at the highest dose. Lilly filed for FDA approval in 2025, the branded product is Foundayo and it belongs in the same conversation as Wegovy and Zepbound rather than replacing either. Here is what the data says and how we think about prescribing it.
- Orforglipron is an oral, small-molecule GLP-1 taken daily with no fasting or water restrictions.
- Trial data shows average weight loss of roughly 11 percent at the highest dose, below injectable tirzepatide and broadly comparable to injectable semaglutide.
- The FDA submission was completed in 2025, with the branded product named Foundayo and we prescribe branded, FDA-approved products only.
- The right choice among oral and injectable options is made from your goals, tolerance, history and preference with a physician.
- The medication is billed by the pharmacy at pharmacy cost with zero markup, separate from the $299 flat membership fee.
What orforglipron actually is
Orforglipron is a small-molecule GLP-1 receptor agonist, taken once daily as a tablet. Unlike the older oral semaglutide tablet, it has no food or water restrictions and no thirty-minute fasting window, which removes the most annoying constraint of existing oral options. It is not a compounded semaglutide tablet and it is not a peptide, which matters because small molecules are cheaper to manufacture at scale and more stable at room temperature.
The branded product is Foundayo and we prescribe it as part of our branded, FDA-approved-only protocol, alongside Wegovy, Zepbound, Ozempic and Mounjaro. We never prescribe compounded GLP-1 under any circumstance.
What the trials showed
The ATTAIN-1 trial in adults with obesity or overweight reported average weight loss of roughly 11 percent at the highest dose over 72 weeks, against about 2 percent for placebo. The ACHIEVE-1 trial in adults with type 2 diabetes showed meaningful HbA1c reductions alongside weight loss. Side effects were the expected class effects: nausea, diarrhea and other gastrointestinal symptoms, generally mild to moderate and easing as titration proceeded.
Read against the injectables, the honest summary is this. Injectable tirzepatide remains the strongest average weight loss in the class, injectable semaglutide sits close behind and orforglipron lands in the range of injectable semaglutide with a simpler delivery route. Individual results vary widely in every trial and the decision is clinical rather than a leaderboard.
The GLP-1 options in 2026
| Medication | Route | Average weight loss in trials |
|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | Up to about 22.5 percent in SURMOUNT-1 |
| Semaglutide (Wegovy) | Weekly injection | About 15 percent in STEP 1 |
| Orforglipron (Foundayo) | Daily tablet | About 11 percent in ATTAIN-1 |
Who it suits
Patients tend to fall into a few honest groups. Some want the strongest average result available and accept the injection. Some want an oral option for travel, storage or preference reasons and accept a somewhat smaller average loss. Some try one and switch, in either direction, under supervision. All three are legitimate.
What no one should do is choose a GLP-1 from a website that profits from the choice. Our economics are built so the fee is the same at every dose and every molecule and the pharmacy bills the medication at cost with zero markup, so the physician's only question is which option fits you best. If your answer changes over time, the protocol changes with it.
What it costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month for the clinical relationship. The first charge is $598, one payment at checkout covering the first two months together, including the clinical intake and your first comprehensive Biomarker Audit. From month three it is $299 per month, month to month and you can cancel anytime after the initial commitment.
The medication is a separate charge, billed directly by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols.
The objection we hear most
Why should I pay $598 before I have lost anything? Because the evaluation is the part that determines whether any GLP-1, oral or injectable, is safe and appropriate for you and that part is skipped everywhere else. The $598 covers the intake, the first comprehensive panel, the reading of the panel and the second month of clinical care and it is the reason the fee never has to climb later. If the structure sounds like the one you have been looking for, the eligibility assessment is the place to start.
FAQ
What is orforglipron?
It is a small-molecule, non-peptide GLP-1 receptor agonist taken as a daily tablet, with no food or water restrictions. Unlike injectable semaglutide or tirzepatide, it is a pill that works at any time of day with or without meals.
How much weight do people lose on orforglipron?
In the ATTAIN-1 trial at the highest dose, participants with obesity or overweight lost an average of roughly 11 percent of body weight over 72 weeks, against about 2 percent for placebo. That sits below injectable tirzepatide and broadly in the range of injectable semaglutide, with individual results varying widely.
How does orforglipron compare with Wegovy and Zepbound?
Orforglipron is oral and simpler to take, while the injectables produce larger average losses, with tirzepatide the strongest. The right choice depends on your goals, tolerance, history and preference and it is a conversation with a physician rather than a ranking on a website.
Is orforglipron FDA approved?
Lilly completed its FDA submission in 2025 with approval expected in 2026 and we prescribe the branded product, Foundayo, within our protocols as availability is confirmed. We do not offer compounded versions under any circumstance.
What are the most common side effects?
Nausea, diarrhea and other gastrointestinal symptoms, which are the class effects seen across GLP-1 medications and which usually ease as titration proceeds. Dose adjustments are made against symptoms, labs and goals rather than on a fixed schedule.
How much does orforglipron cost at GoodLife Health?
The medication is billed by the pharmacy at pharmacy cost with zero markup, separate from the $299 per month membership fee and the $598 first charge covering the first two months. Nothing in our economics rewards a higher dose.
Who is a good candidate for orforglipron?
Adults with obesity or overweight with weight-related metabolic conditions who prefer an oral option, provided they have no contraindication to GLP-1 therapy. A physician determines candidacy from your history, labs and goals, not from a website questionnaire.
Can I switch from an injectable GLP-1 to orforglipron?
Yes, transitions are possible under physician supervision, with the timing and overlap planned rather than improvised. Some patients prefer the oral form for travel or cost reasons and some return to injectables after a trial. Both directions are legitimate clinical decisions.
One last thing
An oral option does not change what the medication is for. It changes what taking it is like. Bring your goals, your history and your tolerance for injections to a physician who can lay out all three branded options with the trial numbers and the costs on the table and make the choice with you rather than for you.
Related guides
- Average weight loss by GLP-1 medication: trial data
- GLP-1 maintenance dose: finding your lowest effective dose
- Cardiometabolic optimization: the definitive guide
References
- Orforglipron in Adults with Obesity or Overweight (ATTAIN-1, New England Journal of Medicine). 2025. doi.org/10.1056/NEJMoa2505617
- Orforglipron in Adults with Type 2 Diabetes and Obesity or Overweight (ACHIEVE-1). 2025. doi.org/10.1056/NEJMoa2412314